We now know that long term infection with certain types of Human Papillomavirus (HPV) is the main cause of cervical cancer. Overseas research has shown that a test for these HPV types is, in fact, a better cervical cancer screening test than the Pap smear.
Compass is a randomised controlled trial to compare 2.5-yearly cytology-based cervical screening with 5-yearly primary HPV screening in Australian women aged 25-69. As of April 2019, we have now completed and closed recruitment in both categories: unvaccinated people and people aged between 25-36 years.
Compass is being carried out by the Australian Centre for the Prevention of Cervical Cancer in collaboration with The Daffodil Centre.
To find out more about what we do or how we can work together, please get in touch.
The Australian Centre for the Prevention of Cervical Cancer (ACPCC) is a not-for-profit organisation with over 55 years of expertise in cancer prevention. Through laboratory and educational services, cancer screening and vaccination registries, and the delivery of digital health solutions, we continue to lead the way in cervical cancer prevention.